Immunotherapy in the management of sepsis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 5, 2002, Pages 317-324

  Sikora, Janusz Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokine agonists and antagonists; Cytokines; Immunotherapy; Monoclonal antibodies; Reactive oxygen species; Sepsis

Indexed keywords

ANTIOXIDANT; AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; CENTOXIN; CORTICOSTEROID; CYTOKINE; CYTOKINE ANTIBODY; EDOBACOMAB; ENDOTOXIN ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B4; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; PENTOXIFYLLINE; REACTIVE OXYGEN METABOLITE; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

CELL ADHESION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; MORTALITY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; RESPIRATORY BURST; REVIEW; SEPSIS; SURVIVAL; TREATMENT OUTCOME; ANIMAL; CHILD; DRUG ANTAGONISM; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; CELL ADHESION; CHILD; CYTOKINES; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; PENTOXIFYLLINE; REACTIVE OXYGEN SPECIES; SEPSIS;

EID: 0036453004     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Abraham E., Wunderink R, and Silverman H. (1995): Efficacay and safety of monoclonal antibody to human tumor necrosis factor in patients with sepsis syndrome. JAMA, 273, 934-941.
2. Alkharfy K. M., Kellum J. A. and Matzke G. R. (2000): Unintended immunomodulation: Part II. Effects of pharmacological agents on cytokine activity. Shock, 13, 346-360.
3. Baumgartner J. D., Glauser M. P., McCutchan J. A., Ziegler E. J., Van Melle G. and Klauber M. R. (1985): Prevention of Gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet, 2, 59-63.
4. Bazzoni F. and Beutler B. (1996): The tumor necrosis factor ligand and receptor families (review). N. Engl. J. Med., 334, 1717-1725.
5. 2 fragment of an anti-tumor necrosis factor α monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock, 1, 237-245.
6. Bone R. C., Balk R. S., Fein A. M., Berl T. M., Wenzel R. P. and Reines H. D. (1995): A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med., 23, 994-1006.
7. Chakraborty A., Blum R. A., Cutler D. R. and Jusko W. J. (1999): Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. Clin. Pharmacol. Ther., 65, 304-318.
8. Chrousos G. P. (1995): The hypothalamic-pituitary-adrenal axis and immune-mediated function. N. Engl. J. Med., 332, 1351-1356.
9. Cometta A., Baumgartner J. D., Lee M. L., Glauser M. P. and the Intravenous Immunoglobulin Collaborative Study Group (1992): Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N. Eng. J. Med., 327, 234-240.
10. Doughty L., Carcilllo J. A., Kaplan S. and Janosky J. (1998): The compensatory anti-inflammatory cytokine interleukin-10 response in pediatric sepsis-induced multiple organ failure. Chest, 113, 1625-1631.
11. Drossou-Agakidou V., Kanakoudi-Tsakalidou F., Sarafidis K., Taparkou A., Tzimouli V., Tsandali H. and Kre-Menopoulos G. (1998): Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and β2 integrin expression. Results of a randomized controlled trial. Eur. J. Pediatr., 157, 583-588.
12. Drossou V., Kanakoudi F., Tzimouli V., Sarafidis K., Taparkou A., Bougiouklis D., Petropoulou T. and Kremenopoulos G. (1997): Impact of prematurity, stress and sepsis on the neutrophil respiratory burst activity of neonates. Biol. Neonate, 72, 201-209.
13. Dunzendorfer S., Schratzberger P., Reinisch N., Kahler C. M. and Wiedermann C. J. (1997): Pentoxifylline differentially regulates migration and respiratory burst activity of the neutrophil. Ann. N. Y. Acad. Sci., 832, 330-340.
14. Engelmann H., Aderka D., Rubinstein M., Rotman D. and Wallach D. (1989): A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem., 264, 1974-1980.
15. Fisher C. J., Dhainaut J. F. A. and Opal S. M. (1994): Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized double-blind, placebo-controlled trial. JAMA, 271, 1836-1843.
16. Fisher C. J., Opal S. M., Dhainaut J. F., Stephens S., Zimmerman J. L., Nightingale P., Harris S. L., Schein R. M., Panacek E. A. and Vincent J. L. (1993): Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med., 21, 318-327.
17. Fuchs A. C., Granovitz E. V., Shapiro L., Vannier E., Lonnemann G., Angel J. B., Kennedy J. S., Rabson A. R., Radwański E., Affrime M. B., Cutler D. L., Grint P. C. and Dinarello C. A. (1996): Clinical, hematological and immunological effects of interleukin-10 in humans. J. Clin. Immunol., 16, 291-303.
18. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C. J and Wretlind B. (1995): Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J. Infect. Dis., 172, 296-301.
19. Gogos C. A., Drosou E., Bassaris H. P. and Skoutelis A. (2000): Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J. Infect. Dis., 181, 176-180.
20. Goldie A. S., Fearon C. H. and Ross J. A. (1995): Natural cytokine antagonist and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA, 274, 172-177.
21. Goode H. F., Cowley H. C., Walker B. E., Howdle P. D. and Webster N. R. (1995): Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit. Care Med., 23, 646-651.
22. Goode H. F. and Webster N. R. (1993): Free radicals and antioxidants in sepsis. Crit. Care Med., 21, 1770-1776.
23. Goris R. J. A. (2000): Pathophysiology of shock in trauma. Eur. J. Surg., 166, 100-111.
24. Hack C. E., Aarden L. A. and Thijs L. G. (1998): Role of cytokines in sepsis. Adv. Immunol., 66, 181-185.
25. Haupt W., Zirngibl H., Stehr A., Riese J., Holzheimer R. G. and Hohenberger W. (1999): Tumor necrosis factor-α and interleukin-10 production in septic patients and the regulatory effect of plasma. Eur. J. Surg., 165, 95-100.
26. Ho Y. S., Howard A. J. and Crapo J. D. (1991): Molecular structure of a functional rat gene for manganese-containing superoxide dismutase. Am. J. Respir. Cell Mol. Biol., 4, 278-286.
27. Kragsbjerg P., Holmberg H. and Vikerfors T. (1996): Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand. J. Infect. Dis., 28, 391-398.
28. Kumar A. and Creery W. D. (2000): The therapeutic potential of interleukin-10 in infection and inflammation. Arch. Immunol. Ther. Exp., 48, 529-538.
29. Koster H., Weiss M., Willeitner A., Detlefsen S., Jeremias I., Zbojan J., Geiger R., Lipowsky G. and Simbruner G. (1998): Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet, 352, 1271-1277.
30. Lauterbach R. and Zembala M. (1996): Pentoxifylline reduces plasma tumor necrosis factor-α concentration in premature infants with sepsis. Eur. J. Pediatr., 155, 404-409.
31. Lechner A. J., Rouben L. R. and Potthoff L. H. (1993): Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ. Shock, 39, 306-315.
32. Lien E., Liabakk N. B., Johnsen A. C., Nonstad U., Sundan A. and Espevik T. (1995): Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur. J. Immunol., 25, 2714-2717.
33. Lloyd S. S., Chang A. K. and Taylor F. B. (1993): Free radicals and septic shock in primates: The role of tumor necrosis factor. Free Radic. Biol. Med., 14, 233-236.
34. Loftis L. L., Meals E. A. and English B. K. (1997): Differential effects of pentoxifylline and interleukin-10 on production of tumor necrosis factor and inducible nitric oxide synthase by murine macrophages. J. Infect. Dis., 175, 1008-1011.
35. Mancuso G., Cusumano V., Genovese F., Gambuzza M., Beninati C. and Teti G. (1997): Role of interleukin-12 in experimental sepsis caused by group B streptococci. Infect. Immun., 65, 3731-3735.
36. Mariscalco M. M. (1998): Infection and the host response. In: Fuhrman B. P.: Pediatric critical care. Mosby, St. Louis, 979-994.
37. Matsukawa A., Hogaboam C. M., Lukacs N. W., Lincoln P. M., Evanoff H. L., Strieter R. M. and Kunkel S. L. (2000): Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J. Immunol., 164, 2738-2744.
38. McCabe W. R., Demaria A., Berberich H. and Johns M. A. (1988): Immunization with rough mutants of Salmonella minnesota: protective activity with IgM and IgG antibody to the R595 (Re chemotype) mutant. J. Infect. Dis., 158, 291-300.
39. McCloskey R. V., Straube R. C., Sanders C., Smith S. M. and Smith C. R. (1994): Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann. Inter. Med., 121, 1-5.
40. Murata A., Kikuchi M., Mishima S., Sakaki S., Goto H., Matsuoka T., Tanaka H., Yukioka T. and Shimazaki S.: (1999): Cytokine imbalance in critically ill patients: SIRS and CARS. Nippon Geka Gakkai Zasshi., 100, 414-418.
41. Nicoletti F., Mancuso G., Cusumano V., Di Marco R., Zaccone P., Bendtzen K. and Teti G. (1997): Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. Eur. J. Immunol., 27, 1580-1583.
42. Nordeen S. K., Suh B. J., Kuhnel B. and Hutchinson C. A. (1990): Structural determinants of a glucocorticoids receptor recognition element. Mol. Endocrinol, 4, 1866-1873.
43. Oismuller C., Mayer N., Micksche M., Steltzer H. and Hammerle A. F. (1995): In vivo modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Shock, 4, 161-165.
44. Paris M. M., Friedland I. R., Ehrett S., Hickey S. M., Olsen K. D., Hausen E., Thonar M. A. and McCracken G. H., JR. (1995): Effect of interleukin-1 receptor antagonist and soluble tumor necrosis factor in animal models of infection. J. Infect. Dis., 171, 161-169.
45. Pascual C., Karzai W., Meier-Hellmann A., Bredle D. L. and Reinhart K. (1997): A controlled study of leukocyte activation in septic patients. Intensive Care Med., 23, 743-748.
46. Petros A., Lamb G. and Leone A. (1994): Effects of nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res., 28, 34-39.
47. Preiser J. C., Lejeune P. and Roman A. (1995): Methylene blue administration in septic shock: A clinical trial. Crit. Care Med., 23, 259-265.
48. Ramano M. J., Kearns G. L. and Kaplan S. (1993): Single-dose pharmacokinetics and safety of HA-1A, a human IgM monoclonal antibody, in pediatric patients with sepsis syndrome. J. Pediatr., 122, 974-981.
49. Roździński E., Spellerberg B., Van Der Flier M., Bhattachargya C., Hoepelman A. I. and Moran M. A. (1995): Peptide from a prokaryotic adhesion blocks leukocyte migration in vitro and in vivo. J. Infect. Dis., 172, 785-793.
50. Sadoff J. (1994): Soluble TNF receptors. Proceedings of the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches, June 3rd, 1994, Munich, Germany.
51. Samson L. M., Allen U. D., Creery W. D., Diaz-Mitoma F. and Singh R. N. (1997): Elevated interleukin-1 receptor antagonist levels in pediatric sepsis syndrome. J. Pediatr., 131, 587-591.
52. Sikora J. P., Chlebna-Sokół D., Da̧browska I., Lipczyński D. and Chrul S. (2001): Proinflammatory cytokine inhibitors, TNF-α and oxidative burst of polymorphonuclear leukocytes in pathogenesis of sepsis in newborns. Arch. Immunol. Ther. Exp., 49, 155-161.
53. Sikora J. P., Chlebna-Sokólł D. and Krzyżańska-Oberbek (2001): Proinflammatory cytokines (IL-6, IL-8), cytokine inhibitors (IL-6sR, sTNFR II) and anti-inflammatory cytokines (IL-10, IL-13) in the pathogenesis of sepsis in newborns and infants. Arch. Immunol. Ther. Exp., 49, 399-404.
54. Starnes H. F., Pearce M. K., Tewari A., Yim J. H., Zon J. C. and Abrams J. S. (1990): Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol., 145, 4185-4191.
55. Szeto Y.-T. and Benzie I. F. (2002): Effects of dietary antioxidants on human DNA ex vivo. Free Radic. Res., 36, 113-118.
56. Tan T. Q., Smith C. W., Hawkins E. P. and Kaplan S. L. (1997): Anti-CD11b monoclonal antibody in an infant rat model of Haemophilus influenzae type B sepsis and meningitis. J. Antimicrob. Chemother., 39, 209-216.
57. Tuomanen E. I., Saukkonen K., Sande S., Cioffe C. and Wright S. D. (1989): Reduction of inflammation, tissue damage and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies. J. Exp. Med., 170, 959-969.
58. Vedder N. B., Fouty B. W., Winn R. K., Harlan J. M. and Rice C. L. (1989): Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock. Surgery, 106, 509-516.
59. Vespasiano M. C., Lewandoski J. R. and Zimmerman J. J. (1993): Longitudinal analysis of neutrophil superoxide anion generation in patients with septic shock. Crit. Care Med., 21, 666-672.
60. Visner G. A., Dougall W. C., Wilson J. M., Burr I. M. and Nick H. S. (1990): Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1 and tumor necrosis factor. J. Biol. Chem., 265, 2856-2864.
61. Vlessis A. A., Goldman R. K. and Trunkey D. D. (1995): New concepts in the pathophysiology of oxygen metabolism during sepsis. Br. J. Surg., 82, 870-876.
62. Wheery J. C., Pennington J. E. and Wenzel R. P. (1993): Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit. Care Med., 21, S436-S440.
63. Zeni F., Pain P., Vindimian M., Gay J. P., Gery P., Bertrand M., Page Y., Page D., Vermesch R. and Bertrand J. C. (1996): Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit. Care Med., 24, 207-214.
64. Ziegler E. J., Fisher C. J., Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E. and the HA-1A Sepsis Study Group (1991): Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med., 324, 429-436.
65. Zimmerman J. J. (1998): Sepsis/septic shock. In: Fuhrman B. P.: Pediatric Critical Care. Mosby, St. Louis, 1088-1100.